Last Updated: September 28, 2026

Vorasidenib - Generic Drug Details

Name: vorasidenib Generic Launch, Drug Patent, and Exclusivity Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

What are the generic drug sources for vorasidenib and what is the scope of patent protection?

Vorasidenib is the generic ingredient in one branded drug marketed by Servier and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for vorasidenib

International Patents:	109
US Patents:	5
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	14
Patent Applications:	1,220
What excipients (inactive ingredients) are in vorasidenib?	vorasidenib excipients list
DailyMed Link:	vorasidenib at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for vorasidenib

Generic Entry Date for vorasidenib^: ⤷ Start Trial* Constraining patent/regulatory exclusivity: ⤷ Start Trial Dosage: TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for vorasidenib

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Institut de Recherches Internationales Servier (I.R.I.S.)	PHASE2
Canadian Cancer Trials Group	PHASE3
European Organisation for Research and Treatment of Cancer - EORTC	PHASE3

See all vorasidenib clinical trials

Pharmacology for vorasidenib

Drug Class	Isocitrate Dehydrogenase 1 Inhibitor Isocitrate Dehydrogenase 2 Inhibitor
Mechanism of Action	Cytochrome P450 3A Inducers Isocitrate Dehydrogenase 1 Inhibitors Isocitrate Dehydrogenase 2 Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for vorasidenib

L01XM	Isocitrate dehydrogenase (IDH) inhibitors
L01X	OTHER ANTINEOPLASTIC AGENTS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for vorasidenib

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Servier	VORANIGO	vorasidenib	TABLET;ORAL	218784-002	Aug 6, 2024		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Servier	VORANIGO	vorasidenib	TABLET;ORAL	218784-001	Aug 6, 2024		RX	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Servier	VORANIGO	vorasidenib	TABLET;ORAL	218784-002	Aug 6, 2024		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Servier	VORANIGO	vorasidenib	TABLET;ORAL	218784-001	Aug 6, 2024		RX	Yes	No	⤷ Start Trial	⤷ Start Trial	Y	Y		⤷ Start Trial
Servier	VORANIGO	vorasidenib	TABLET;ORAL	218784-002	Aug 6, 2024		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Servier	VORANIGO	vorasidenib	TABLET;ORAL	218784-001	Aug 6, 2024		RX	Yes	No	⤷ Start Trial	⤷ Start Trial	Y	Y		⤷ Start Trial
Servier	VORANIGO	vorasidenib	TABLET;ORAL	218784-002	Aug 6, 2024		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for vorasidenib

Subscribe to access the full database, or Start Trial
Country	Patent Number	Title	Estimated Expiration
Argentina	096902		⤷ Start Trial
Argentina	131555		⤷ Start Trial
Australia	2014289744		⤷ Start Trial
Australia	2019201179		⤷ Start Trial
Brazil	112016000561		⤷ Start Trial
Brazil	122017014843		⤷ Start Trial
Canada	2917358		⤷ Start Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Supplementary Protection Certificates for vorasidenib

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3019483	122026000022	Germany	⤷ Start Trial	PRODUCT NAME: VORASIDENIB ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ ODER HYDRAT DAVON; AUTHORISATION NO/DATE: EU/1/25/1912 20250917
3019483	C20265008	Finland	⤷ Start Trial
3019483	CR 2026 00011	Denmark	⤷ Start Trial	PRODUCT NAME: VORASIDENIB ELLER ET FARMACEUTISK ACCEPTABELT SALT ELLER HYDRAT DERAF; REG. NO/DATE: EU/1/25/1912 20250919
3019483	LUC50043	Luxembourg	⤷ Start Trial	PRODUCT NAME: VORASIDENIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OR HYDRATE THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/25/1912 20250919
3019483	301370	Netherlands	⤷ Start Trial	PRODUCT NAME: VORASIDENIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF HYDRAAT DAARVAN; REGISTRATION NO/DATE: EU/1/25/1912 20250919
3019483	2026C/707	Belgium	⤷ Start Trial	PRODUCT NAME: VORASIDENIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF HYDRAAT DAARVAN; AUTHORISATION NUMBER AND DATE: EU/1/25/1912 20250919
3019483	C03019483/01	Switzerland	⤷ Start Trial	PRODUCT NAME: VORASIDENIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 69364 15.11.2024
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.